Identification of Potential Predictor of Biochemical Recurrence in Prostate Cancer
Jingchao Wei,Xiaohang Wu,Yuxiang Li,Xiaowu Tao,Bo Wang,Guangming Yin
DOI: https://doi.org/10.2147/IJGM.S355435
IF: 2.145
2022-05-13
International Journal of General Medicine
Abstract:Jingchao Wei, 1 Xiaohang Wu, 2 Yuxiang Li, 2 Xiaowu Tao, 2 Bo Wang, 2 Guangming Yin 2 1 Department of Urology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, People's Republic of China; 2 Department of Urology, The Third Xiangya Hospital of Central South University, Changsha, People's Republic of China Correspondence: Guangming Yin, Email Background: Prostate cancer is a common malignancy in men. Radical prostatectomy is one of the primary treatment modalities for patients with prostate cancer. However, early identification of biochemical recurrence is a major challenge for post-radical prostatectomy surveillance. There is a lack of reliable predictors of biochemical recurrence. The purpose of this study was to explore potential biochemical recurrence indicators for prostate cancer. Materials and Methods: We analyzed transcriptomic data of cases with biochemical recurrence in The Cancer Genome Atlas (TCGA). Then, we performed integrative bioinformatics analyses to establish a biochemical recurrence predictor model of prostate cancer. Results: There were 146 differentially expressed genes (DEGs) between prostate cancer and normal prostate, including 12 upregulated and 134 downregulated genes. Comprehensive pathway enrichment analyses revealed that these DEGs were associated with multiple cellular metabolic pathways. Subsequently, according to the random assignment principle, 208 patients were assigned to the training cohort and 205 patients to the validation cohort. Univariate Cox regression analysis showed that 7 genes were significantly associated with the biochemical recurrence of prostate cancer. A model consisting of 5 genes was constructed using LASSO regression and multivariate Cox regression to predict biochemical recurrence of prostate cancer. Expression of PAH and AOC1 decreased with an increasing incidence of prostate cancer, whereas expression of DDC, LINC01436 and ORM1 increased with increasing incidence of prostate cancer. Kaplan–Meier curves and receiver operator characteristic (ROC) curves indicated that the 5-gene model had reliable utility in identifying the risk of biochemical recurrence of prostate cancer. Conclusion: This study provides a model for predicting prostate cancer recurrence after surgery, which may be an optional indicator for postoperative follow-up. Keywords: prostate cancer, biochemical recurrence, predictor, signature, follow-up Prostate cancer is a considerable health threat to middle-aged and older men, and its mortality is ranked fifth among all tumors in males. 1 It is well known that the growth and progression of prostate cancer depend on androgen. Androgen deprivation therapy is an effective treatment strategy and is widely used for treating prostate cancer. 2 Also, there has been increasing interest in the role of localized therapies in recent years. 3 However, the biological characteristics of prostate cancer could be either indolent or highly aggressive. 4 Therefore, biochemical recurrence (BCR) is a leading concern for patients after radical prostatectomy or androgen deprivation therapy, as it often represents a progression of the cancer to a stage that is more difficult to be treated. The incidence of prostate cancer biochemical recurrence is around 15% to 30% within 5 years and about 40% within 10 years after radical prostatectomy. 5 Once biochemical recurrence occurs, many prostate cancer patients are inclined to progress to be resistant to androgen deprivation therapy, which is also called castration-resistant prostate cancer (CRPC). 1 CRPC usually leads to death within 2 to 4 years. 6 Massive efforts have resulted in new biomarkers for early detection and prognosis of prostate cancer, but few reliable predictive markers of prostate cancer progression. Multiple factors, including the Gleason score, pathological clinic staging, prostate-specific antigen (PSA), and surgical margin, fail to predict biochemical recurrence accurately. PSA is a vital biomarker of prostate cancer for postoperative diagnosis, screening, and follow-up. Previous studies investigated the significance of PSA above 0.2 ng/mL post radical prostatectomy. 7 PSA testing facilitates earlier prediction of PSA recurrence. However, not all patients with detectable PSA levels will experience clinical progression. In general, patients with advanced prostate cancer are no longer suitable for surgical treatment. Therefore, the prognostic value of T stage for biochemical recurrence of prostate cancer is not very clear. Furthermore, traditional imaging technology has limited value in identifying BCR at extremely low PSA le -Abstract Truncated-
medicine, general & internal